{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-22-000037","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.109933+00:00","generated_at":"2026-06-21T23:25:32.453626+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Werewolf Therapeutics reports Q3 2022 net loss of $11.9M; first patient dosed in WTX-124 Phase 1/1b trial","bullets":["Net loss of $11.9M for Q3 2022 vs $13.8M in Q3 2021; cash and equivalents $140.5M as of Sept 30.","First patient dosed in Phase 1/1b trial of WTX-124 (IL-2 INDUKINE) as monotherapy and in combination with KEYTRUDA; initial data expected Q4 2023.","FDA cleared IND for WTX-330 (IL-12 conditionally activated molecule); Phase 1 study in immunotherapy-resistant tumors starting.","Collaboration revenue from Jazz licensing agreement was $5.0M in Q3 2022 (none in prior year); R&D expenses $13.1M.","Cash runway through at least Q2 2024, supported by existing cash, anticipated collaboration revenue, and term loan facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-22-000037","json":"https://secwatch.observer/filing/0001785530-22-000037.json","markdown":"https://secwatch.observer/filing/0001785530-22-000037.md","text":"https://secwatch.observer/filing/0001785530-22-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553022000037/0001785530-22-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553022000037/howl-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:25:32.453626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"591be7c73230d352b9928d61478d3923773c214f","claim":"Werewolf Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $5.0 million.","evidence_excerpt":"sufficient to fund its operational expenses and capital expenditure requirements through at least the second quarter of 2024. • Collaboration revenue: Collaboration revenue was $5.0 million for the third quarter of 2022, compared to zero for the same period in 2021. Collaboration revenue is related to amortization of the $15.0 million upfront payment received in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553022000037/0001785530-22-000037-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$5.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}